Anteris
Creating Life-Changing Outcomes in Transcatheter Aortic Valve Replacement

Around 62 million people globally suffer from severe aortic stenosis (AS)–a valvular heart disease caused by progressive calcification of the aortic valve that leads to narrowing at the opening. The condition mainly affects older people and increases with age, affecting up to five percent of the elderly population, and is fatal if not treated at the right time. For a long time, surgical aortic valve replacement or thoracotomy has been the standard of care for people with aortic stenosis. However, patients above 80, termed as high-risk patients, have been excluded from the surgery since the surgical risks and mortality rate is very high. The vital need to find an alternative treatment option for elderly patients who suffer from severe symptomatic aortic stenosis paved the way for transcatheter aortic valve replacement (TAVR)–a minimally invasive, catheter-based treatment procedure that takes about 25 to 40 minutes to replace the function of the aortic valve.

However, in the TAVR space, the critical challenge for surgeons and patients is finding a replacement valve that delivers better hemodynamics performance and can last the patient’s whole life. Most of the aortic valves in the market are inept and unreliable due to the poor design, the problem of calcification, and the lack of durability. Thus, even after treatment, patients end up with mild stenosis, and the short-lived aortic valves fail to deliver lasting health results to young and active patients.

This industry narrative is what Anteris intends to change. With Wayne Paterson, who has comprehensive experience and expertise in the pharma space at the helm, the company is focused on developing next-generation technologies that can create life-changing outcomes. “We are the only company focused on tissue science, valve design, and delivery system in the TAVR space providing products that last longer and works better,” says Wayne Paterson, the CEO and managing director of Anteris. Understanding the growing need of the TAVR space to bring aortic valves with consistency to treat aortic stenosis, Anteris has developed a suite of technologies.

Anteris’ medical devices rely heavily on its proprietary ADAPT® tissue technology– an anti-calcification treatment platform technology. ADAPT®, a chemical treatment process, removes the animal DNA from the xenograft tissues and converts it into pure collagen with improved strength, flexibility, biocompatibility, and durability. The technology is FDA approved and has been used in surgical repair for over 20,000 patients globally. Anteris is the only company with ten-year no-calcification data in humans and thus uniquely positioned in the TAVR market.

Leveraging the remarkable ADAPT® technology, Anteris has built a novel and unique product, DurAVR™–the first and only 3D single-piece aortic valve, thereby initiating a dynamic step in the aortic valve space. The state-of-the-art design, along with the anti-calcification treatment, enables DurAVR™ to restore normal pre-disease hemodynamics, making it far more anatomically correct than any other device currently available in the market. The patient recovery with DurAVR™ is far swifter, and the valve has the potential to be the most functional and long-term cure for the treatment of aortic stenosis. “Our product is the most efficient and durable aortic valve, giving patients a solution for 10 to 15 years or more. Many studies have proven the superiority of DurAVR™ over the products of contenders in terms of clinical performance and durability,” Paterson explains.

We are the only company focused on tissue science, valve design, and delivery system in the TAVR space providing products that last longer and works better

Anteris has solidified its position as a structural heart company with its unique and groundbreaking product for the TAVR market that delivers amazing health outcomes. Consistently recording a high growth rate, the global TAVR market stock is hiking up, and the company forges ahead with better plans for the coming years. Embarking on an early feasibility study (EFS) at the outset, Anteris is on its way to obtain CE Marking. “We have a broader vision for the product and the company concerning our go-tomarket strategies, partnerships, and managing the market revenue,” concludes Paterson.